What after Lucian Boldea’s Insider Unload of Eastman Chemical Company (EMN) Stock?; 3 Analysts Covering Tandem Diabetes Care, Inc. (TNDM)

Among 9 analysts covering Tandem Diabetes Care (NASDAQ:TNDM), 3 have Buy rating, 1 Sell and 5 Hold. Therefore 33% are positive. Tandem Diabetes Care had 20 analyst reports since August 5, 2015 according to SRatingsIntel. The rating was maintained by Deutsche Bank with “Buy” on Wednesday, November 2. Zacks downgraded the shares of TNDM in report on Friday, August 28 to “Buy” rating. Feltl & Co downgraded the stock to “Buy” rating in Wednesday, November 2 report. On Wednesday, November 2 the stock rating was maintained by Wedbush with “Outperform”. The stock of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has “Sell” rating given on Wednesday, August 5 by Zacks. The stock of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has “Hold” rating given on Friday, September 4 by Zacks. As per Thursday, January 14, the company rating was downgraded by Bank of America. Stifel Nicolaus downgraded Tandem Diabetes Care, Inc. (NASDAQ:TNDM) on Wednesday, November 2 to “Hold” rating. The rating was maintained by Deutsche Bank with “Buy” on Monday, August 10. As per Thursday, November 3, the company rating was downgraded by Piper Jaffray. See Tandem Diabetes Care, Inc. (NASDAQ:TNDM) latest ratings:

20/11/2017 Broker: Bank of America Rating: Underperform Old Target: $20 New Target: $2 Maintain
17/11/2017 Broker: Robert W. Baird Rating: Hold New Target: $3.0 Maintain
05/10/2017 Broker: Piper Jaffray Rating: Hold New Target: $1.5 Maintain

The Eastman Chemical Co’s Senior Vice President, Lucian Boldea, an insider unloaded – 3,325 Eastman Chemical Co’s shares, based on the average $95.0 for each share. These insider shares lately had a value of about $315,875 US Dollars.

Investors sentiment increased to 1.18 in Q3 2017. Its up 0.04, from 1.14 in 2017Q2. It improved, as 32 investors sold Eastman Chemical Company shares while 175 reduced holdings. 67 funds opened positions while 178 raised stakes. 115.86 million shares or 0.58% less from 116.54 million shares in 2017Q2 were reported. Bb&T Secs Lc invested in 0.01% or 7,729 shares. Thompson Davis holds 0.03% or 203 shares in its portfolio. Tiverton Asset Limited Liability has 0.01% invested in Eastman Chemical Company (NYSE:EMN) for 1,301 shares. Mariner Wealth Ltd Com accumulated 4,639 shares or 0.02% of the stock. 7,890 are owned by Jensen Invest Inc. Lombard Odier Asset Management (Switzerland) Sa invested in 21,773 shares or 0.19% of the stock. Raymond James Fincl Svcs Inc has invested 0.01% in Eastman Chemical Company (NYSE:EMN). South Dakota Inv Council has 427,113 shares for 0.78% of their portfolio. Murphy Mngmt reported 0.09% of its portfolio in Eastman Chemical Company (NYSE:EMN). Mckinley Capital Mgmt Lc Delaware invested in 2,894 shares or 0.01% of the stock. Ahl Llp invested in 184,918 shares. Texas Permanent School Fund accumulated 40,150 shares. The Netherlands-based Ing Groep Nv has invested 0.02% in Eastman Chemical Company (NYSE:EMN). Aldebaran Financial Incorporated owns 34,521 shares or 2.16% of their US portfolio. Cipher L P holds 0.16% or 24,106 shares.

Among 17 analysts covering Eastman Chemical Company (NYSE:EMN), 9 have Buy rating, 2 Sell and 6 Hold. Therefore 53% are positive. Eastman Chemical Company has $120.0 highest and $73 lowest target. $104.25’s average target is 7.10% above currents $97.335 stock price. Eastman Chemical Company had 56 analyst reports since July 30, 2015 according to SRatingsIntel. As per Wednesday, July 12, the company rating was maintained by Citigroup. Barclays Capital maintained the shares of EMN in report on Monday, February 5 with “Equal-Weight” rating. Jefferies maintained the shares of EMN in report on Tuesday, February 6 with “Buy” rating. The stock has “Equal Weight” rating by Barclays Capital on Monday, January 30. The rating was maintained by KeyBanc Capital Markets on Monday, October 30 with “Buy”. On Tuesday, August 23 the stock rating was maintained by Cowen & Co with “Outperform”. The rating was maintained by RBC Capital Markets with “Hold” on Tuesday, September 5. The stock of Eastman Chemical Company (NYSE:EMN) has “Sector Perform” rating given on Monday, October 31 by RBC Capital Markets. The rating was maintained by Citigroup on Monday, April 18 with “Buy”. The stock of Eastman Chemical Company (NYSE:EMN) has “Hold” rating given on Monday, July 10 by RBC Capital Markets.

Eastman Chemical Company manufactures and sells materials, specialty additives, chemicals, and fibers in the United States and internationally. The company has market cap of $13.92 billion. The companyÂ’s Additives & Functional Products segment offers specialty coalescents, specialty and commodity solvents, paint additives, and specialty polymers; hydrocarbon and rosin resins; sulfur and antidegradant rubber additives; performance resins and amine-derivative building blocks; heat transfer and aviation fluids; formic-acid based solutions; and metam based soil fumigants, thiram and ziram based fungicides, and plant growth regulators. It has a 9.65 P/E ratio. The Company’s products are used in coatings, tires, consumables, building and construction, animal nutrition, care chemical, crop protection, and energy markets.

The stock decreased 0.19% or $0.185 during the last trading session, reaching $97.335. About 228,680 shares traded. Eastman Chemical Company (NYSE:EMN) has risen 7.60% since February 13, 2017 and is uptrending. It has underperformed by 9.10% the S&P500.

Since August 22, 2017, it had 0 insider purchases, and 4 insider sales for $1.65 million activity. HORNBAKER RENEE J sold $337,720 worth of stock. Shares for $479,024 were sold by Stuckey Perry on Tuesday, October 31. 4,417 shares were sold by WARMACK DAMON CARY, worth $435,516. $399,360 worth of Eastman Chemical Company (NYSE:EMN) was sold by DEMERITT STEPHEN R on Wednesday, February 7.

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company has market cap of $22.77 million. The companyÂ’s flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its disposable insulin cartridge, and an infusion set. It currently has negative earnings. It also provides t:flex insulin delivery system that includes t:flex pump, its 480-unit disposable insulin cartridge, and an infusion set; and t:slim G4 insulin delivery system, a touch-screen pump with an integrated CGM system.

The stock decreased 6.64% or $0.16 during the last trading session, reaching $2.25. About 337,885 shares traded. Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has declined 86.78% since February 13, 2017 and is downtrending. It has underperformed by 103.48% the S&P500.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: